Drug Profile


Alternative Names: CGS 19755; Sefotel

Latest Information Update: 25 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Neuroprotectants
  • Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain injuries; Cerebrovascular disorders; Cognition disorders; Stroke

Most Recent Events

  • 21 Mar 2000 A study has been added to the adverse events and therapeutic trials sections
  • 31 Dec 1998 Discontinued - Phase-II for Cerebrovascular disorders in Japan (IV)
  • 31 Dec 1998 Discontinued - Phase-II for Cognition disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top